Silence Therapeutics says additional results from APOLLO phase 1 study published

Silence Therapeutics announced additional results from the APOLLO phase 1 study of zerlasiran in subjects with baseline lipoprotein(a), or Lp(a), levels at or over 150 nmol/L were published in the Journal of the American Medical Association. The single ascending and multiple dose trial enrolled 32 healthy participants and 36 patients with atherosclerotic cardiovascular disease, or ASCVD, and Lp(a) concentrations greater than or equal to150 nmol/L. Results from the single ascending dose portion of the trial in healthy participants were previously published in the April 2022 issue of JAMA. Today’s JAMA publication reviews findings from the extended 365 day follow up of healthy participants who received the two highest zerlasiran doses of 300 or 600 mg and 201 days of follow up for ASCVD patients administered 2 doses, the company stated. “Positive phase 1 data published in JAMA demonstrate treatment with zerlasiran produced sustained reductions in Lp(a) concentrations with a well-tolerated profile using varying dosing regimens. The promising findings from this study are particularly encouraging as we complete the phase 2 study for zerlasiran and underscore our commitment to address this major unmet need in cardiovascular disease,” said Curtis Rambaran, MD, Chief Medical Officer at Silence and senior author of the publication.